NASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $29.96 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.07 +0.11 (+0.37%) As of 05/22/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Roivant Sciences Stock (NASDAQ:ROIV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$29.88▼$30.8750-Day Range$26.41▼$32.4152-Week Range$10.59▼$32.79Volume5.87 million shsAverage Volume6.30 million shsMarket Capitalization$21.44 billionP/E RatioN/ADividend YieldN/APrice Target$33.05Consensus RatingModerate Buy Company Overview Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines. The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health. In addition to traditional drug development, Roivant leverages digital platforms and data-driven tools—such as those developed by its technology affiliate, Datavant—to enhance patient recruitment, real-world evidence collection, and trial analytics. This integrated approach is designed to reduce the cost and time associated with bringing new medicines to market. Headquartered in Basel, Switzerland, with major offices in New York and London, Roivant Sciences operates on a global scale and collaborates with academic institutions, biotechnology firms, and larger pharmaceutical partners. Its subsidiaries manage their own clinical programs while benefiting from Roivant’s shared infrastructure, regulatory expertise, and commercial strategy. This model allows each “Vant” to maintain a clear focus on its specific therapeutic goal while tapping into centralized support services. Roivant was founded by entrepreneur Vivek Ramaswamy and is currently led by Chief Executive Officer Matthew Gline. Under their leadership, the company has built a team of experienced biopharma professionals and has raised significant venture and public financing to fuel its pipeline. Through its innovative corporate structure and commitment to technology-enabled development, Roivant continues to pursue its mission of delivering transformative therapies to patients with unmet medical needs.AI Generated. May Contain Errors. Read More Roivant Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreROIV MarketRank™: Roivant Sciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 580th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRoivant Sciences has a consensus price target of $33.05, representing about 10.3% upside from its current price of $29.96.Amount of Analyst CoverageRoivant Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -49.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -49.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.24% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 4.83.Change versus previous monthShort interest in Roivant Sciences has recently increased by 10.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.43 News SentimentRoivant Sciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest18 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,654,456.00 in company stock.Percentage Held by Insiders10.80% of the stock of Roivant Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Stock News HeadlinesEric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) StockMay 23 at 7:50 AM | insidertrades.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Roivant Sciences (ROIV)May 22 at 5:52 PM | theglobeandmail.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 25 at 1:00 AM | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Citius Oncology (CTOR)May 22 at 2:50 AM | theglobeandmail.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call TranscriptMay 21, 2026 | insidermonkey.comRoivant Sciences Ltd. 2025 Q4 - Results - Earnings Call PresentationMay 21, 2026 | seekingalpha.comRoivant (ROIV) Climbs 15% on Swing to ProfitsMay 20, 2026 | insidermonkey.comRoivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readoutsMay 20, 2026 | seekingalpha.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $21.70 at the beginning of the year. Since then, ROIV stock has increased by 38.1% and is now trading at $29.96. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Wednesday, May, 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The firm earned $2.52 million during the quarter, compared to analysts' expectations of $3.41 million. Roivant Sciences had a negative trailing twelve-month return on equity of 20.54% and a negative net margin of 3,629.19%. Read the conference call transcript. Who are Roivant Sciences' major shareholders? Roivant Sciences' top institutional shareholders include Dimensional Fund Advisors LP (1.04%), Assenagon Asset Management S.A. (0.99%), Rubric Capital Management LP (0.70%) and ADAR1 Capital Management LLC (0.46%). Insiders that own company stock include Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Daniel Allen Gold, Frank Torti, Eric Venker, Keith S Manchester, Global Investors Lp Viking, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roivant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/20/2026Today5/25/2026Bernstein 42nd Annual Strategic Decisions Conference5/29/2026Jefferies Global Healthcare Conference 20266/03/2026Investor update6/09/2026Next Earnings (Estimated)8/10/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ROIV's financial health is in the Green zone, according to TradeSmith. ROIV has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ROIV CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees860Year Founded2014Price Target and Rating Average Price Target for Roivant Sciences$33.05 High Price Target$42.00 Low Price Target$16.50 Potential Upside/Downside+10.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$171.98 million Net Margins-3,629.19% Pretax Margin-3,203.12% Return on Equity-20.54% Return on Assets-19.43% Debt Debt-to-Equity RatioN/A Current Ratio18.37 Quick Ratio30.66 Sales & Book Value Annual Sales$8.26 million Price / Sales2,595.93 Cash FlowN/A Price / Cash FlowN/A Book Value$7.39 per share Price / Book4.05Miscellaneous Outstanding Shares715,701,000Free Float638,405,000Market Cap$21.44 billion OptionableOptionable Beta1.14 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ROIV) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
